Compare · OM vs STXS
OM vs STXS
Side-by-side comparison of Outset Medical Inc. (OM) and Stereotaxis Inc. (STXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both OM and STXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- OM is the larger of the two at $1.64B, about 4.3x STXS ($383.3M).
- Over the past year, OM is down 61.1% and STXS is down 3.0% - STXS leads by 58.1 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- OM has more recent analyst coverage (13 ratings vs 6 for STXS).
- Company
- Outset Medical Inc.
- Stereotaxis Inc.
- Price
- $4.53-0.88%
- $1.94-0.77%
- Market cap
- $1.64B
- $383.3M
- 1M return
- +28.37%
- +3.47%
- 1Y return
- -61.13%
- -3.00%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2020
- News (4w)
- 6
- 6
- Recent ratings
- 13
- 6
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Stereotaxis Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Latest OM
- SEC Form DEFA14A filed by Outset Medical Inc.
- SEC Form DEF 14A filed by Outset Medical Inc.
- SEC Form 4 filed by Elliott Derick A.
- SEC Form 3 filed by new insider Elliott Derick A.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Outset Medical Names Derick Elliott as Executive Vice President of Commercial
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Amendment: New insider Leonard Braden Michael claimed ownership of 1,902,201 shares (SEC Form 3)
- General Counsel Brottem John L. sold $9,521 worth of shares (2,842 units at $3.35), decreasing direct ownership by 8% to 32,935 units (SEC Form 4)
- Chair and CEO Trigg Leslie sold $11,259 worth of shares (3,361 units at $3.35), decreasing direct ownership by 3% to 102,342 units (SEC Form 4)
Latest STXS
- Stereotaxis Announces First MAGiC Procedures in the United States
- Stereotaxis to Report First Quarter 2026 Financial Results on May 12, 2026
- Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Stereotaxis Announces Definitive Agreement to Acquire Robocath
- SEC Form 4 filed by Peery Kimberly R.
- Stereotaxis Announces FDA Clearance and Launch of Synchrony System
- Amendment: SEC Form 10-K/A filed by Stereotaxis Inc.
- SEC Form DEFA14A filed by Stereotaxis Inc.
- SEC Form DEF 14A filed by Stereotaxis Inc.
- SEC Form EFFECT filed by Stereotaxis Inc.